Geron Corp (NASDAQ:GERN) Q4 2017 Institutional Investor Sentiment Steady

April 17, 2018 - By Winifred Garcia

Geron Corporation (NASDAQ:GERN) Logo

Sentiment for Geron Corp (NASDAQ:GERN)

Geron Corp (NASDAQ:GERN) institutional sentiment decreased to 0.93 in Q4 2017. Its down -0.04, from 0.97 in 2017Q3. The ratio fall, as 38 funds opened new and increased positions, while 41 sold and reduced their holdings in Geron Corp. The funds in our partner’s database now hold: 58.72 million shares, down from 61.75 million shares in 2017Q3. Also, the number of funds holding Geron Corp in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 30 Increased: 25 New Position: 13.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $640.98 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

The stock increased 5.27% or $0.1998 during the last trading session, reaching $3.9898. About 7.08M shares traded or 0.64% up from the average. Geron Corporation (NASDAQ:GERN) has risen 126.87% since April 17, 2017 and is uptrending. It has outperformed by 115.32% the S&P500.

Nj State Employees Deferred Compensation Plan holds 0.09% of its portfolio in Geron Corporation for 280,000 shares. Fernwood Investment Management Llc owns 16,000 shares or 0.02% of their US portfolio. Moreover, A.R.T. Advisors Llc has 0.01% invested in the company for 85,300 shares. The New Jersey-based Brave Asset Management Inc has invested 0.01% in the stock. Family Management Corp, a New York-based fund reported 10,200 shares.#img1#

Geron Corporation (NASDAQ:GERN) Ratings Coverage

Ratings analysis reveals 50% of Geron Corp’s analysts are positive. Out of 2 Wall Street analysts rating Geron Corp, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $4.0 while the high is $7.0. The stock’s average target of $5.50 is 37.85% above today’s ($3.9898) share price. GERN was included in 2 notes of analysts from March 18, 2018. The firm has “Buy” rating by Piper Jaffray given on Monday, March 19. The stock has “Hold” rating by Stifel Nicolaus on Sunday, March 18.

Geron Corporation (NASDAQ:GERN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: